Tuhura Biosciences Inc (HURA) Stock Price, Quote & News

Company Profile

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 813 875 6600

Website: www.tuhurabio.com

Address:

10500 University Center Drive, Suite 110, Tampa, United States

ZacksSCR Aug. 26 at 1:14 PM

$HURA: Milestone Progression Over Next 12 Months https://buff.ly/1VJZees

0 · Reply

DiamondDelta Aug. 23 at 6:07 PM

$NMTC $HURA I am betting big on OLOX, this has the recipe to see a parabolic move next week, look below why!! OLOX -Bitcoin miner+AI fit the theme, makes the most sense. $11 book value, 20 RSI on the daily 96 short squeeze score. Just the bounce in itself could be 200-300%. OLOX put it on ur watch!

0 · Reply

topstockalerts Aug. 23 at 5:03 PM

After Hours Top Gainers PT2 $CDTG $CYPH $NMTC $BTCS $HURA

0 · Reply

topstockalerts Aug. 22 at 9:34 PM

After Hours Top Gainers PT2 $CDTG $CYPH $NMTC $BTCS $HURA

0 · Reply

topstockalerts Aug. 22 at 12:44 AM

After Hours Top Gainers PT2 $CDTG $CYPH $NMTC $BTCS $HURA

0 · Reply

2TrustHim Aug. 21 at 9:28 PM

$HURA http://archive.fast-edgar.com/20260821/A222622FZZ2RM2Z222TR2MYQCWPBOZ22D282

0 · Reply

2TrustHim Aug. 21 at 9:27 PM

$HURA Does The Loan Agreement Prevent Dilution And It Should Be Going Up???

0 · Reply

Twood47 Aug. 21 at 8:37 PM

$HURA why did this stop

0 · Reply

TuHURA_IR Aug. 19 at 5:13 PM

$HURA Early-stage programs are often evaluated by the milestones that reduce scientific and regulatory risk over time. Our ADC platform is progressing through that sequence, from humanized mouse model data to lead optimization, IND-enabling studies, and ultimately a first-in-human study. Our President and CEO walks through the milestones that could shape the program over the coming year. https://youtu.be/BYkgoaFXiys

1 · Reply

Gotsomescrewsmissing Aug. 18 at 6:57 PM

$HURA HURA: All proposals passed, including director elections and share issuance, with no stockholder questions — TradingView News https://share.google/9lBKx34WrDdcK5GiS

1 · Reply

TuHURA Biosciences Transcript: AGM 2026

Aug 14, 2026, 7:45 AM EDT - 12 days ago

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Aug 14, 2026, 7:30 AM EDT - 12 days ago

TuHURA Biosciences Earnings release: Q2 2026

Aug 14, 2026, 7:30 AM EDT - 12 days ago

TuHURA Biosciences Quarterly report: Q2 2026

Aug 12, 2026, 12:30 PM EDT - 14 days ago

TuHURA Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 11, 2026, 7:00 AM EDT - 15 days ago

TuHURA Biosciences Slides: Corporate presentation

Jul 22, 2026, 7:40 AM EDT - 5 weeks ago

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

Jul 9, 2026, 8:00 AM EDT - 6 weeks ago

TuHURA Biosciences Proxy statement: Proxy filing

Jul 9, 2026, 8:00 AM EDT - 6 weeks ago

TuHURA Biosciences Proxy statement: Proxy filing

Jun 26, 2026, 8:00 AM EDT - 2 months ago

TuHURA Biosciences Proxy statement: Proxy filing

2026-06-15T11:53:47.000Z - 2 months ago

TuHURA Biosciences files IND application with FDA for study of TBS-2025

Jun 15, 2026, 7:45 AM EDT - 2 months ago

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

May 15, 2026, 5:00 PM EDT - 3 months ago

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

May 15, 2026, 7:00 AM EDT - 3 months ago

TuHURA Biosciences Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

TuHURA Biosciences Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

TuHURA Biosciences Slides: Corporate presentation

May 12, 2026, 7:30 AM EDT - 3 months ago

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

2026-04-27T08:45:56.000Z - 4 months ago

TuHURA Biosciences initiated with an Outperform at Citizens

Apr 22, 2026, 7:30 AM EDT - 4 months ago

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

2026-04-15T12:20:48.000Z - 4 months ago

TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

Apr 7, 2026, 7:45 AM EDT - 5 months ago

TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations

Apr 1, 2026, 7:45 AM EDT - 5 months ago

TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Mar 31, 2026, 7:00 AM EDT - 5 months ago

TuHURA Biosciences Earnings release: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 5 months ago

TuHURA Biosciences Annual report: Q4 2025

Mar 23, 2026, 7:45 AM EDT - 5 months ago

Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers

Feb 27, 2026, 7:30 AM EST - 6 months ago

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 24, 2026, 5:20 PM EST - 6 months ago

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

2026-02-17T12:50:50.000Z - 6 months ago

TuHURA Biosciences files INDA for TBS-2025 in blood-related cancers

Feb 17, 2026, 7:45 AM EST - 6 months ago

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

Feb 12, 2026, 7:45 AM EST - 6 months ago

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-02T12:50:49.000Z - 7 months ago

TuHURA Biosciences says FDA grants Orphan Drug Designation to IFx-2.0

Feb 2, 2026, 7:45 AM EST - 7 months ago

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma

2026-01-09T11:16:01.000Z - 8 months ago

TuHURA Biosciences price target lowered to $10 from $12 at H.C. Wainwright

2025-12-15T13:06:01.000Z - 9 months ago

TuHURA Biosciences announces release of Kintara’s CVR

Dec 15, 2025, 7:50 AM EST - 9 months ago

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

2025-12-11T12:35:31.000Z - 9 months ago

TuHURA Biosciences provides updates across portfolio

Dec 11, 2025, 7:30 AM EST - 9 months ago

TuHURA Biosciences Provides Corporate Update Following Recent Financing

2025-12-09T14:55:32.000Z - 9 months ago

TuHURA Biosciences announces $15.6M registered direct offering

Dec 9, 2025, 9:49 AM EST - 9 months ago

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

2025-12-08T12:55:12.000Z - 9 months ago

TuHURA Biosciences presents research on potential role of DOR at ASH

Dec 8, 2025, 7:50 AM EST - 9 months ago

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

2025-11-14T17:20:32.000Z - 10 months ago

TuHURA Biosciences price target lowered to $8 from $15 at Maxim

Nov 14, 2025, 7:00 AM EST - 10 months ago

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 14, 2025, 7:00 AM EST - 10 months ago

TuHURA Biosciences Earnings release: Q3 2025

Nov 14, 2025, 7:00 AM EST - 10 months ago

TuHURA Biosciences Quarterly report: Q3 2025

2025-11-03T22:35:14.000Z - 10 months ago

TuHURA Biosciences files $250M mixed securities shelf

Nov 3, 2025, 9:01 AM EST - 10 months ago

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 7:00 AM EST - 10 months ago

TuHURA Biosciences Registration statement: Registration filing

Sep 18, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences Registration statement: Registration filing

Aug 20, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 1 year ago

TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 14, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Quarterly report: Q2 2025

2025-08-12T20:40:47.000Z - 1 year ago

TuHURA Biosciences files to sell 4.76M shares of common stock for holders

Aug 12, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences Registration statement: Registration filing

Jul 10, 2025, 4:00 AM EDT - 1 year ago

Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development

2025-07-01T12:55:33.000Z - 1 year ago

TuHURA Biosciences included in Russell 3000 and 2000 Indexes

Jul 1, 2025, 8:50 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 30, 2025, 8:50 AM EDT - 1 year ago

TuHURA Biosciences Completes Acquisition of Kineta

2025-06-24T12:05:10.000Z - 1 year ago

TuHURA Biosciences initiates Phase 3 approval trial of IFx-2.0 in carcinoma

Jun 24, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

2025-06-23T21:05:17.000Z - 1 year ago

TuHURA Biosciences, Kineta stockholders approve merger and related proposals

Jun 23, 2025, 5:00 PM EDT - 1 year ago

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals

2025-06-23T17:48:27.000Z - 1 year ago

TuHURA Biosciences initiated with a Buy at Brookline

Jun 9, 2025, 8:00 AM EDT - 1 year ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

Jun 3, 2025, 9:58 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Jun 2, 2025, 8:03 AM EDT - 1 year ago

TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting

May 15, 2025, 4:10 PM EDT - 1 year ago

TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 15, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Earnings release: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference

May 5, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)

Apr 28, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting

Apr 7, 2025, 8:24 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

Apr 1, 2025, 8:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Annual report: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TuHURA Biosciences Earnings release: Q4 2024

Mar 11, 2025, 8:05 AM EDT - 1 year ago

TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D.

Mar 10, 2025, 9:00 AM EDT - 1 year ago

TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

TuHURA Biosciences, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Dec 20, 2024, 10:18 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS and HURA on Behalf of Shareholders

VTS

Dec 12, 2024, 8:45 AM EST - 1 year ago

TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.

Nov 25, 2024, 8:35 AM EST - 1 year ago

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

Nov 14, 2024, 7:00 AM EST - 1 year ago

TuHURA Biosciences Quarterly report: Q3 2024

Oct 23, 2024, 8:30 AM EDT - 2 years ago

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Oct 22, 2024, 9:00 AM EDT - 2 years ago

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

Oct 17, 2024, 4:35 PM EDT - 2 years ago

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

Oct 16, 2024, 12:54 PM EDT - 2 years ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

Oct 16, 2024, 11:58 AM EDT - 2 years ago

Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

Oct 15, 2024, 4:15 PM EDT - 2 years ago

Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

ZacksSCR Aug. 26 at 1:14 PM

$HURA: Milestone Progression Over Next 12 Months https://buff.ly/1VJZees

0 · Reply

DiamondDelta Aug. 23 at 6:07 PM

0 · Reply

topstockalerts Aug. 23 at 5:03 PM

After Hours Top Gainers PT2 $CDTG $CYPH $NMTC $BTCS $HURA

0 · Reply

topstockalerts Aug. 22 at 9:34 PM

After Hours Top Gainers PT2 $CDTG $CYPH $NMTC $BTCS $HURA

0 · Reply

topstockalerts Aug. 22 at 12:44 AM

After Hours Top Gainers PT2 $CDTG $CYPH $NMTC $BTCS $HURA

0 · Reply

2TrustHim Aug. 21 at 9:28 PM

$HURA http://archive.fast-edgar.com/20260821/A222622FZZ2RM2Z222TR2MYQCWPBOZ22D282

0 · Reply

2TrustHim Aug. 21 at 9:27 PM

$HURA Does The Loan Agreement Prevent Dilution And It Should Be Going Up???

0 · Reply

Twood47 Aug. 21 at 8:37 PM

$HURA why did this stop

0 · Reply

TuHURA_IR Aug. 19 at 5:13 PM

1 · Reply

Gotsomescrewsmissing Aug. 18 at 6:57 PM

$HURA HURA: All proposals passed, including director elections and share issuance, with no stockholder questions — TradingView News https://share.google/9lBKx34WrDdcK5GiS

1 · Reply

TuHURA_IR Aug. 17 at 4:46 PM

$HURA Antibody-drug conjugates have become one of the fastest-growing areas in oncology, but not every platform approaches them the same way. Rather than delivering a cytotoxic payload directly to tumor cells, our ADC platform is designed to target the immune-suppressive cells that limit the effectiveness of immunotherapy. Watch this segment for a closer look at the science behind our approach. https://youtu.be/ylYDnzmylG8

0 · Reply

PastaSlobCFA Aug. 17 at 5:09 AM

$HURA $3.00 this week easily!!!

2 · Reply

toesinthesand Aug. 16 at 3:38 AM

$HURA going to 10

1 · Reply

steven1x Aug. 14 at 1:30 PM

$HURA https://ir.tuhurabio.com/news-events/press-releases/detail/48/tuhura-biosciences-reports-second-quarter-2026-financial-results-and-provides-a-corporate-update

0 · Reply

TuHURA_IR Aug. 14 at 1:12 PM

$HURA As our pipeline expands, investors increasingly ask how the different programs fit together. One mission drives everything in our pipeline: overcoming resistance to cancer immunotherapy. IFx-2.0, TBS-2025, and our ADC platform each address a different aspect of that challenge, with milestones expected across the coming year. Hear Dr. James Bianco recap how the programs fit together and where they are headed. https://youtu.be/b1UIcmk5cDg

0 · Reply

Danielord Aug. 14 at 12:09 AM

$HURA 1,5 next week

0 · Reply

MoneyMacG Aug. 14 at 12:02 AM

$HURA this could be stupid in a good way

0 · Reply

Gotsomescrewsmissing Aug. 13 at 10:34 PM

$PLUG $FLY $HURA Lets have a strong finish to the year!

0 · Reply

Danielord Aug. 13 at 9:30 PM

$HURA 0,5 this year❤️

0 · Reply

Danielord Aug. 13 at 8:04 PM

$HURA where is your er hahaha free short🥰🥰🥰🥰

0 · Reply

PastaSlobCFA Aug. 13 at 7:43 PM

$HURA WHAT HAPPENED???

0 · Reply

PastaSlobCFA Aug. 13 at 6:51 PM

$HURA BIG PUMP COMING TOMORROW

0 · Reply

Market Cap	137.01M
Revenue (ttm)	0.00
Net Income (ttm)	-30.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.47

Volume	142,640
Avg Vol	455,932
Day's Range	N/A - N/A
Shares Out	63.73M
Stochastic %K	8%
Beta	-0.01
Analysts	Strong Sell
Price Target	$7.87